Factor XIIIa crosslinking sites on fibrin

Factor XIIIa crosslinking sites on fibrin are specific amino acid residues, primarily glutamine and lysine, located on the alpha and gamma chains of fibrin molecules (Schmitt et al., 2011; PMID: 21239771). These sites serve as the substrate for the transglutaminase activity of activated Factor XIII (FXIIIa), which catalyzes the formation of covalent epsilon-(gamma-glutamyl)lysine isopeptide bonds (Muszbek et al., 2011; PMID: 21323911). This biochemical process is critical for the mechanical stabilization of the blood clot, transforming a loose fibrin mesh into a robust, insoluble network. Furthermore, crosslinking increases the clot's resistance to fibrinolysis by plasmin, thereby extending the lifespan of the thrombus (Standeven et al., 2007; PMID: 17627770). In clinical contexts, these sites are significant because the stability they provide to thrombi is a major factor in the persistence of obstructive clots in conditions such as deep vein thrombosis and ischemic stroke. Therapeutic targeting of these sites involves the use of small molecules or peptides, such as those developed by Zedira GmbH (e.g., Z006, T101), which act as inhibitors of the crosslinking process (Zedira GmbH, 2024). By inhibiting the crosslinking at these specific sites, the resulting clots remain more susceptible to degradation, potentially improving the efficacy of thrombolytic therapies. This approach represents a novel strategy for managing thrombotic diseases by modulating clot structure rather than just preventing clot formation.

Other names

Fibrin cross-linking sitesFXIIIa substrate sites on fibrinGamma-chain cross-linking sitesAlpha-chain cross-linking sitesFibrinogen cross-linking sitesFXIIIa-mediated cross-linking sites

The mechanism involves the inhibition of the transglutaminase-mediated formation of isopeptide bonds between specific glutamine (e.g., Gln398/399 on the gamma chain) and lysine (e.g., Lys406 on the gamma chain) residues on fibrin (Schmitt et al., 2011; PMID: 21239771). Drugs targeting this process, such as Factor XIIIa inhibitors or substrate mimetics, prevent the covalent stabilization of the fibrin matrix, leading to a clot that is mechanically weaker and more susceptible to plasmin-mediated fibrinolysis (Muszbek et al., 2011; PMID: 21323911).